JP2007526312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007526312A5 JP2007526312A5 JP2007501867A JP2007501867A JP2007526312A5 JP 2007526312 A5 JP2007526312 A5 JP 2007526312A5 JP 2007501867 A JP2007501867 A JP 2007501867A JP 2007501867 A JP2007501867 A JP 2007501867A JP 2007526312 A5 JP2007526312 A5 JP 2007526312A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- composition according
- nervous system
- meridamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000012902 Nervous system disease Diseases 0.000 claims 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- UNSKIISCJFJWTL-WIDVRGBZSA-N meridamycin Chemical compound C1C(O)C(C)C(O)CC(O)CC(O)\C(C)=C\C(C)CC(C)C(O)C(/CC)=C/CC(C(\C)=C\C(C)C(C)O)OC(=O)C2CCCN2C(=O)C(=O)C2(O)C(C)CCC1O2 UNSKIISCJFJWTL-WIDVRGBZSA-N 0.000 claims 6
- DGKUOWHAUIWQTM-UHFFFAOYSA-N meridamycin Natural products C1C(O)C(C)C(O)CC(O)CC(O)C(C)=CC(C)CC(C)C(O)C(CC)=CCC(C(C)=CC(C)C(C)O)OC(=O)C2CCCCN2C(=O)C(=O)C2(O)C(C)CCC1O2 DGKUOWHAUIWQTM-UHFFFAOYSA-N 0.000 claims 6
- 208000009829 Lewy Body Disease Diseases 0.000 claims 4
- 201000002832 Lewy body dementia Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006289 Rett Syndrome Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 2
- 238000000862 absorption spectrum Methods 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54943004P | 2004-03-02 | 2004-03-02 | |
| PCT/US2005/006246 WO2005084673A1 (en) | 2004-03-02 | 2005-02-25 | Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007526312A JP2007526312A (ja) | 2007-09-13 |
| JP2007526312A5 true JP2007526312A5 (enExample) | 2008-04-10 |
Family
ID=34919492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501867A Withdrawn JP2007526312A (ja) | 2004-03-02 | 2005-02-25 | 神経保護および／または神経再生剤としての非免疫抑制性イムノフィリンリガンド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050197356A1 (enExample) |
| EP (1) | EP1720548A1 (enExample) |
| JP (1) | JP2007526312A (enExample) |
| CN (1) | CN1929837A (enExample) |
| AU (1) | AU2005219389A1 (enExample) |
| BR (1) | BRPI0508084A (enExample) |
| CA (1) | CA2556771A1 (enExample) |
| WO (1) | WO2005084673A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0508224A (pt) * | 2004-03-02 | 2007-07-17 | Wyeth Corp | composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto |
| JP2008501342A (ja) * | 2004-06-03 | 2008-01-24 | ワイス | 複合ポリケチドを生成するための生合成遺伝子クラスター |
| TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| JP2009529049A (ja) * | 2006-03-07 | 2009-08-13 | ワイス | 神経障害の治療のためのメリダマイシン類似体 |
| TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
| TW200831096A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| CA2676613A1 (en) * | 2007-01-29 | 2008-08-07 | Wyeth | Immunophilin ligands and methods for modulating immunophilin and calcium channel activity |
| EP3139174B1 (en) | 2009-09-24 | 2018-11-07 | Etienne Baulieu | Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9302016D0 (en) * | 1993-02-02 | 1993-03-17 | Sandoz Ltd | Compounds |
| UA41884C2 (uk) * | 1993-11-05 | 2001-10-15 | Амерікан Хоум Продактс Корпорейшн | Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US6242468B1 (en) * | 1997-02-27 | 2001-06-05 | Jia-He Li | Carbamate and urea compositions and neurotrophic uses |
| US7041283B1 (en) * | 2001-02-16 | 2006-05-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods of using immunophilin binding drugs to improve integration and survival of neuronal cell transplants |
-
2005
- 2005-02-25 US US11/066,031 patent/US20050197356A1/en not_active Abandoned
- 2005-02-25 CN CNA2005800070342A patent/CN1929837A/zh active Pending
- 2005-02-25 BR BRPI0508084-3A patent/BRPI0508084A/pt not_active IP Right Cessation
- 2005-02-25 CA CA002556771A patent/CA2556771A1/en not_active Abandoned
- 2005-02-25 WO PCT/US2005/006246 patent/WO2005084673A1/en not_active Ceased
- 2005-02-25 JP JP2007501867A patent/JP2007526312A/ja not_active Withdrawn
- 2005-02-25 AU AU2005219389A patent/AU2005219389A1/en not_active Withdrawn
- 2005-02-25 EP EP05723912A patent/EP1720548A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102892857B1 (ko) | 케타민 파모에이트 및 이의 용도 | |
| JP2008520589A5 (enExample) | ||
| US8168800B2 (en) | Aβ-binding small molecules | |
| JP2023507408A5 (enExample) | ||
| JP2007500757A5 (enExample) | ||
| CY1105507T1 (el) | Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες | |
| RU98109951A (ru) | Применение 2-амино-4-(4-фторбензиламино)-1-этоксикарбониламинобензола для профилактики и лечения острой и хронической церебральной недостаточности, а также нейродегенеративнных заболеваний | |
| WO2003077869A3 (en) | Neuroprotective spirostenol pharmaceutical compositions | |
| JP2022539152A5 (enExample) | ||
| JP2006515370A5 (enExample) | ||
| CA2818161A1 (en) | Novel compound and medical use thereof | |
| JP2009526834A5 (enExample) | ||
| JP2022538286A5 (enExample) | ||
| WO2010005581A4 (en) | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) | |
| EP2022778A1 (en) | A crystalline form of (R,R)-tramadol-(S)-naproxene salt | |
| JP2023518640A5 (enExample) | ||
| JP2010501591A (ja) | ３−（３−インドリル）プロピオン酸カルシウム塩およびそれから３−（３−インドリル）プロピオン酸の遊離酸を作る方法 | |
| CN106946701B (zh) | 一种水杨酸基富马酸盐衍生物及在治疗帕金森症和其他神经退行性疾病应用 | |
| HK1042053A1 (zh) | 替安乃亭在製取治療神經變性病變的藥物中的應用 | |
| WO2005042561A3 (en) | Neural regeneration peptides and methods of use | |
| EP1509216B1 (de) | Wirkstoffsalze und ester von 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol und 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol | |
| RU2825336C2 (ru) | Кетамин памоат и его применение | |
| JPH0840902A (ja) | 末梢神経障害および中枢神経変性疾患の治療に有用な医薬組成物 | |
| CA3118954C (en) | Ketamine pamoate and use thereof | |
| JP2009529049A5 (enExample) |